$LLY (Eli Lilly and Company)

$LLY {{ '2016-10-05T12:44:16+0000' | timeago}} • Announcement

The current vaccine portfolio of Boehringer Ingelheim Vetmedica Inc., which is to be acquired by Elanco U.S. Inc., a subsidiary of $LLY, has experienced revenue growth over the past three years. $LLY expects the deal to add to GAAP earnings in 2019 and to non-GAAP earnings in 2018.

$LLY {{ '2017-11-13T19:49:26+0000' | timeago}} • Announcement

$LLY names Philip Johnson as SVP and Treasurer effective Jan. 1, 2018. Johnson, the current VP for IR, will continue to lead IR functionalities.

$LLY {{ '2017-11-06T12:38:31+0000' | timeago}} • Announcement

$LLY and $INCY said that rheumatoid arthritis drug Baricitinib gave better outcomes compared to the Humira drug. Lilly plans to resubmit the New Drug Application (NDA) with the FDA for Baricitinib before the end of Jan. 2018. In Sept., Lilly and Incyte reported that Baricitinib showed better outcomes for treating a type of skin inflammation.

$LLY {{ '2017-10-31T19:39:59+0000' | timeago}} • Announcement

$LLY, which announced its plan to layoff 3,500 jobs or 8% of its global workforce in early Sept., had worldwide headcount of 41,225 as of Sept. 30, 2017. This is a decline of 1,175 positions or 2.8% from 42,400 worldwide employees as of Sept. 30, 2016.

$LLY {{ '2017-10-24T21:28:19+0000' | timeago}} • Announcement

For FY17, $LLY hiked its revenue outlook to $22.4-22.7Bil, primarily due to uptake trends for new pharmaceutical products. Lilly's GAAP EPS expectation was lowered to $1.73-1.83 versus prior outlook of $2.51-2.61. However, non-GAAP EPS estimate was increased to $4.15-4.25 from the previous range of $4.10-4.54.

$LLY {{ '2017-10-24T21:25:34+0000' | timeago}} • Announcement

When announcing its 3Q17 results, $LLY said that it is looking for an IPO, sale, merger or spin off its Elanco Animal Health business. Lilly plans to give an update on this regard before the middle of 2018. Animal Health business, which was acquired for $5.4Bil in Jan. 2015 from $NVO, had contributed $740.6MM to Lilly's revenue in 3Q17.

$LLY {{ '2017-10-24T21:23:05+0000' | timeago}} • Announcement

$LLY's GAAP net income fell 29% to $556MM and EPS dropped 27% to $0.53 in 3Q17, hurt by the higher asset impairment and restructuring charges. Revenue rose 9% to $5.67Bil, helped by the volume growth from new pharmaceutical products. Excluding items, Lilly earned $1.05 per share, up 19% from a year ago quarter.

$LLY {{ '2017-10-24T13:58:12+0000' | timeago}} • Infographic

$LLY Eli Lilly and Company Earnings AlphaGraphic: Q3 2017 Highlights

$LLY {{ '2017-10-23T12:23:01+0000' | timeago}} • Announcement

As part of the anticipated $850MM capital investments in US, $LLY plans to invest $72MM in its Indianapolis facility for an insulin manufacturing project. CEO David Ricks said that the current US tax reform proposal would cut the corporate tax rate to 20%, put in place a territorial system, and maintain tax credits for R&D.

$LLY {{ '2017-10-18T18:15:06+0000' | timeago}} • Announcement

$LLY inks a deal with Germany-based CureVac to develop and market up to 5 cancer vaccines. Lilly would pay CureVac $50MM as upfront fee and make an equity investment of EUR45MM. If successful, CureVac would receive more than $1.7Bil as milestone payment. Subject to the closing, Lilly expects to incur a charge of $0.03 per share to its earnings.

$LLY {{ '2017-10-16T19:27:03+0000' | timeago}} • Announcement

The BoD of $LLY declared a dividend for 4Q17 of $0.52 per share, payable on Dec. 8, 2017 to shareholders as of Nov. 15, 2017.

$LLY {{ '2017-10-12T14:50:24+0000' | timeago}} • Announcement

FDA grants priority review for $LLY's breast cancer drug Verzenio, which was approved by the agency on Sept. 28. 2017. Now, FDA will speed up the review and will take action within eight months.  On Oct. 10, 2017, Lilly announced that Verzenio failed in the Phase 3 study for treating advanced lung cancer.

$MCK {{ '2017-10-11T18:31:37+0000' | timeago}} • Announcement

Biologics, a $MCK Specialty Health oncology pharmacy services company, has been selected by $LLY to be in the limited distribution network for Verzenio (abemaciclib), $LLY's first oral oncolytic indicated for metastatic breast cancer. Verzenio obstructs growth of cancer cells by specifically blocking cyclin-dependent kinases, CDK4 and CDK6.

$LLY {{ '2017-10-10T13:44:54+0000' | timeago}} • Announcement

$LLY's advanced lung cancer treatment drug Verzenio flunks in meeting the end goal of overall survival among the 453 patients in the Phase 3 JUNIPER trial study. The most common adverse events experienced by these patients were diarrhea, fatigue, decreased appetite, and nausea. Last month, FDA approved Verzenio for the treatment of breast cancer.

$LLY {{ '2017-10-06T18:13:20+0000' | timeago}} • Announcement

The U.S. Patent and Trademark Office (PTO) ruled in favor of $LLY for its cancer drug Alimta. The review was initiated by Neptune Generics and Sandoz Inc and PTO concluded that claims of the Alimta vitamin regimen patent are valid. If the patent is upheld through all remaining challenges, Alimta would maintain U.S. exclusivity until May 2022.

$LLY {{ '2017-10-05T17:01:58+0000' | timeago}} • Announcement

$LLY announced that its breast cancer drug Verzenio (abemaciclib) will be available in U.S. by mid Oct.-2017. On Sept. 28, 2017, FDA approved Lilly's Verzenio.

$LLY {{ '2017-10-04T18:08:34+0000' | timeago}} • Announcement

Humalog Junior KwikPen, a prefilled and disposable half-unit insulin pen from $LLY, will be available now in U.S. for treating type 1 and type 2 diabetes. In June 2017, Humalog Junior KwikPen was approved by the FDA and it is expected to get the EU's approval later in 2017.

$LLY {{ '2017-09-29T12:44:44+0000' | timeago}} • Announcement

$LLY announced about the retirements of two senior leaders. Maria Crowe, President of manufacturing operations will retire in Dec. 2017 and Jan Lundberg, EVP for science & technology and President of Lilly Research Labs, will retire at the end of May 2018. In June, Lilly announced that its current CFO Derica Rice would retire at 2017-end.

$LLY {{ '2017-09-29T12:33:31+0000' | timeago}} • Announcement

$LLY announces senior leadership changes for finance, R&D and manufacturing, effective 2018. This includes the promotion of Josh Smiley as CFO and Dan Skovronsky as SVP for science & technology and president of Lilly Research Labs. Also, Myles O'Neill will take over the lead role in manufacturing and CIO Aarti Shah elevated as an executive officer.

$LLY {{ '2017-09-28T21:06:48+0000' | timeago}} • Announcement

FDA approves $LLY's breast cancer drug Verzenio (abemaciclib), which will compete with $PFE's Ibrance and $NVS' Kisqali drugs. Verzenio works by blocking certain molecules involved in promoting the growth of cancer cells. The National Cancer Institute estimated that approximately 252,710 women will be diagnosed with breast cancer this year.

$LLY {{ '2017-09-25T13:18:33+0000' | timeago}} • Announcement

Geisinger and Boehringer Ingelheim, on behalf of its partnership with $LLY, announced that they will create a model to predict the three major outcomes associated with type 2 diabetes. The new model will allow to predict the complications from cardiovascular death, kidney failure and hospitalization for heart failure.

Recent Transcripts

ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
ARQL (ArQule Inc.)
Thursday, November 9 2017 - 2:00pm
FGEN (FibroGen, Inc.)
Wednesday, November 8 2017 - 10:00pm
OPK (Opko Health, Inc.)
Wednesday, November 8 2017 - 9:30pm
REGN (Regeneron Pharmaceuticals, Inc.)
Wednesday, November 8 2017 - 1:30pm
IONS (Ionis Pharmaceuticals, Inc.)
Tuesday, November 7 2017 - 4:30pm
ATRS (Antares Pharma Inc.)
Tuesday, November 7 2017 - 1:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, November 7 2017 - 1:00pm
PTLA (Portola Pharmaceuticals, Inc.)
Monday, November 6 2017 - 9:30pm
CAH (Cardinal Health, Inc.)
Monday, November 6 2017 - 1:30pm
TXMD (TherapeuticsMD, Inc.)
Monday, November 6 2017 - 1:00pm
IMGN (ImmunoGen, Inc.)
Friday, November 3 2017 - 12:00pm
BDX (Becton, Dickinson and Company)
Thursday, November 2 2017 - 12:00pm
EXEL (Exelixis, Inc.)
Wednesday, November 1 2017 - 9:00pm
SYN (Synthetic Biologics Inc.)
Wednesday, November 1 2017 - 8:30pm
AMRN (Amarin Corporation plc)
Wednesday, November 1 2017 - 12:00pm
AGIO (Agios Pharmaceuticals, Inc.)
Wednesday, November 1 2017 - 12:00pm
ARRY (Array BioPharma Inc.)
Tuesday, October 31 2017 - 1:00pm
ACOR (Acorda Therapeutics, Inc.)
Tuesday, October 31 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm

AlphaGraphics you may like